Meningioma

Meningiomas arise from the coverings of the brain or spinal cord. Many grow slowly. A skull-base tumor near vision or hearing nerves, a lesion involving a major venous sinus, and a spinal tumor compressing the cord pose different problems even when their size is similar.

Symptoms can include seizures, changes in vision, hearing, smell or cognition, and limb weakness. New weakness, a seizure or rapidly worsening vision needs prompt assessment. A long-standing headache alone does not establish the diagnosis.

MRI often supports a provisional diagnosis, while tissue obtained during surgery establishes the type and grade. CT can clarify bone involvement. Molecular testing is especially useful in higher-grade, recurrent or diagnostically uncertain disease; not every observed incidental lesion requires a biopsy.

CNS WHO grades range from 1 to 3. A pathogenic TERT promoter alteration or homozygous CDKN2A/B deletion can establish grade 3 even without classic anaplastic appearance. Rhabdoid or papillary appearance alone no longer automatically means grade 3. New molecular-risk recommendations can refine difficult cases, but should not be confused with a new official WHO edition.

For an asymptomatic, incidentally found or slowly growing lesion, scheduled MRI and clinical review may be appropriate. The plan should state the first reassessment date, what degree of growth matters and which symptoms should trigger earlier contact.

Observation is less suitable when there is sustained growth, relevant symptoms or a threat to an important nerve or structure. Age, other illnesses, swelling and the feasibility of future treatment also matter. Stable scans do not remove the need to review cognitive or functional changes.

Surgery can establish the diagnosis, relieve pressure and control the tumor. The aim is the safest useful removal, including involved dura or bone where feasible. A surgeon may deliberately leave tumor attached to a major vessel or nerve to protect function, then discuss monitoring or radiotherapy.

Ask what benefit surgery is expected to bring and which functions are at risk. The operative assessment of removal and postoperative MRI should be read together. A complete removal reduces recurrence risk but does not eliminate long-term follow-up.

Completely removed grade 1 tumors are commonly monitored; selected residual grade 1 tumors may be watched or irradiated. Residual grade 2 and grade 3 tumors usually make the case for postoperative radiotherapy stronger. Treatment near the optic apparatus or brainstem may require fractionation rather than single-session radiosurgery.

ROAM/EORTC-1308 randomized 157 patients after complete removal of newly diagnosed atypical meningioma. Five-year disease-free survival was about 80% with radiotherapy versus 64% with observation. This supports offering a postoperative radiotherapy discussion even when no tumor remains visible. It does not prove an overall-survival advantage or apply automatically to grade 1 tumors.

The trial reported grade 2–3 radiation-related serious adverse events in 5 of 66 assessed radiotherapy patients. Recurrence prevention must be weighed against potential delayed effects, location, baseline cognition and the patient’s priorities. A lower recurrence risk does not mean radiotherapy is free of harm.

At recurrence, review whether another operation or carefully planned reirradiation is feasible. A somatostatin-receptor PET scan can help when the extent of tumor or recurrent disease is unclear, especially at the skull base or in bone. A positive scan does not by itself establish tumor grade.

Once local options are exhausted, trials of molecularly selected drugs, immunotherapy or radioligand therapy may be relevant. NF2, AKT1, SMO or other findings can help identify a study, but an apparent target is not proof that a drug works. SSTR-directed PRRT remains investigational in meningioma and should not be presented as equivalent to its established uses in other tumor types.

Bring a complete history of hormonal medicines, including contraception and treatment for other conditions. Certain progestogens have regulatory warnings about meningioma risk; the formulation, dose and duration matter. A diagnosis should prompt a prescriber-led medication review, not an assumption that every hormone medicine has the same risk.

Most tumor mutations are acquired rather than inherited. Multiple tumors, a young age, family history or particular pathology can justify genetic counseling—for example, assessment for NF2-related schwannomatosis or selected SMARCE1/BAP1-associated conditions. A tumor-only result is not itself a hereditary diagnosis.

Follow-up includes MRI and assessment of symptoms and function. Its intensity depends on grade, remaining tumor, prior growth and treatment. Higher-risk disease generally needs closer review, and a previously stable lesion can still change later.

Discuss hearing and vision assessment, seizure control, memory, fatigue and mood, as well as physical, occupational or speech rehabilitation. Depending on tumor location and radiation exposure, endocrine follow-up may also be relevant. Return to work and driving should be planned around neurologic recovery and local requirements.

Bring original and serial MRI files, pathology including grade and molecular findings, the operation report, radiotherapy plans and a medication list. Record changes in daily function, not only the scan measurements.

Ask what makes observation or intervention appropriate, whether the pathology needs review, what function a planned residual protects, and how the latest grade 2 radiotherapy evidence applies to your situation. For experimental treatment, ask what evidence supports it and what established local options remain.